Navigation Links
Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
Date:9/16/2009

atment of type 2 diabetes, ulcerative colitis and rheumatoid arthritis, and APOPTONE(R) (HE3235), a next-generation compound in a clinical trial for the treatment of late-stage prostate cancer. For more information on Hollis-Eden, visit its website at www.holliseden.com.

This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the potential and prospects of Hollis-Eden Pharmaceuticals, Inc. regaining and maintaining compliance with the listing standards of the NASDAQ Global Market and its drug discovery program and its drug candidates. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hollis-Eden's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for TRIOLEX(R) (HE3286), APOPTONE(R) (HE3235) or any other investigational drug candidate; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on thes
'/>"/>

SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... 30, 2014 Grace Century portfolio project, ... Manganello, Chairman of the Board, to the National Stem ... appointment was made by the Ministry of Health on behalf ... , More than a year after Bahamian Parliament ... Prime Minister Perry Christie said the government has completed the ...
(Date:10/30/2014)... severe flooding that devastated a wide swath of Colorado ... bridges, roads and other infrastructure had been upgraded or ... of Colorado Denver. , "People need to understand the ... associate professor of structural engineering at the CU Denver ... the study. "There is an assumption that a bridge ...
(Date:10/27/2014)... -- Kalorama Information says that PCR is demonstrating its ... the United States and is the dominant ... the FDA,s Emergency Use Authorization (EUA) to authorize the emergency ... of the Ebola virus was an indication that the ... IVD industry and its biennial survey on diagnostics markets ...
Breaking Biology Technology:Rancho BioSciences Manually Curated TCGA Data Sets Available 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3CU Denver study says upgrading infrastructure could reduce flood damage 2Kalorama: PCR The Go-to Test in Ebola Fight 2Kalorama: PCR The Go-to Test in Ebola Fight 3
... Danaher Corporation (NYSE:,DHR) announced that Executive Vice President ... presenting at the Robert W. Baird Industrial,Conference in ... 1:55 p.m. CST.,The audio will be simultaneously webcast ... a leading manufacturer of Professional,Instrumentation, Medical Technologies, Industrial ...
... ) reports third quarter 2008 results for the period,ended September 30, ... -- Sales increased 3.2% (-1.7% excluding foreign currency) compared to ... the quarter was up $1.7 million to $11.4 million ... of cash was $92.0 million at the end of third quarter ...
... Company,(Nasdaq: PRGO ; TASE) today announced that its ... share, payable on December 16, 2008 to,shareholders of record ... per share represents a ten percent increase over $0.05 ... Company is a leading global healthcare supplier that develops,manufactures ...
Cached Biology Technology:Cambrex Reports Third Quarter 2008 Results 2Cambrex Reports Third Quarter 2008 Results 3Cambrex Reports Third Quarter 2008 Results 4Cambrex Reports Third Quarter 2008 Results 5Cambrex Reports Third Quarter 2008 Results 6Cambrex Reports Third Quarter 2008 Results 7Cambrex Reports Third Quarter 2008 Results 8Cambrex Reports Third Quarter 2008 Results 9Cambrex Reports Third Quarter 2008 Results 10Cambrex Reports Third Quarter 2008 Results 11Cambrex Reports Third Quarter 2008 Results 12Cambrex Reports Third Quarter 2008 Results 13Cambrex Reports Third Quarter 2008 Results 14
(Date:10/27/2014)... CA – October 28, 2014 – A new randomized ... proprietary blend of collagen and calcium, KoACT®, was far ... the leaching of calcium from bones and rebuilding new ... PubMed at: http://www.ncbi.nlm.nih.gov/pubmed/25314004 , ahead of print in ... The research was conducted by Bahram H. Arjmandi, PhD, ...
(Date:10/27/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and ... focused on the growing mobile commerce market issues a ... Chief Technology Officer. Mr Tunnell examines the case for ... the variety of new payment solutions being released, consumers ... has its own attributes that promise to make payments ...
(Date:10/27/2014)... results from a safety and immunogenicity study, which ... that a live attenuated enterotoxigenic Escherichia coli ... a novel adjuvant, provided significant protection against disease. ... vaccine/adjuvant combination, which was 58.5 percent efficacious in ... highly rigorous ETEC human challenge model. The vaccine/adjuvant ...
Breaking Biology News(10 mins):New RCT: KoACT® beats calcium and vitamin D for optimal bone strength 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 2Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 3Media Alert; NXT-ID Chief Technology Officer Comments on Why You Need a Smart Wallet 4Clinical results indicate vaccine candidate highly efficacious against bacterial diarrhea 2
... The University of Manchester have made a surprising finding ... have big implications for research into human healing and ... salamanders have remarkable regenerative capacities, in contrast to mammals, ... tail a new one will regenerate within a week. ...
... Fujian and Shenzhen, China- An international research consortium, led ... completed the first genome sequence of the diamondback moth ... crops. This work provides wider insights into insect adaptation ... sustainable pest management. The latest study was published online ...
... release is available in French and German ... Royal Veterinary College London. Scientists have been able to ... the backbone of early tetrapods, the earliest four-legged animals. High-energy ... to reconstruct the backbones of the 360 million year old ...
Cached Biology News:The secrets of a tadpole's tail and the implications for human healing 2The secrets of a tadpole's tail and the implications for human healing 3The genome of diamondback moth provides new clues for sustainable pest management 2The genome of diamondback moth provides new clues for sustainable pest management 3Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 2Scientists reassemble the backbone of life with a particle acceleratorynchrotron X-rays 3
... The Vibratome Company has joined forces with ... the Vibratome 411301 Tissue Chopper. This tissue ... sections of tissue for metabolic experiments and ... irregular specimens available at biopsy or from ...
... The Vibratome Company has joined forces ... introduce the Vibratome 800 Tissue Chopper. This ... prepare sections of tissue for metabolic experiments ... and irregular specimens available at biopsy or ...
... design, The Bioactive peptides are molecules of ... biological behaviour or activity which can be ... diagnostic, chemical and agro-food applications. In this ... peptides with superior properties for therapeutic applications. ...
... within neurons in vesicles called synaptosomes. ... synaptic bouton. Synaptosomes may be ... other cellular debris. Abnormalites in neurotransmitter ... pathological condtions. Conditions of release ...
Biology Products: